[Adjuvant chemotherapy using adriamycin and cisplatin in infiltrating cancer of the bladder. Prospective study of 49 cases].
Between January 1981 and March 1988, we prospectively treated 49 patients with infiltrating bladder cancer (Stages B2, C and D1 of the classification of Marshall or pT3-T4, No/N+ of the UICC classification) by adjuvant combination chemotherapy with Adriamycin and Cisplatin. Chemotherapy started 4 to 8 weeks after radical surgery with total prostatocystectomy in males or anterior pelvectomy in females associated in all cases with bilateral ilio-obturator pelvic lymph node dissection. With a mean follow up of 34 months (3 to 85 months) 32 patients are still alive and disease free (17/23 stage B2, 8/15 stage C, and 7/11 stage D1). The crude disease free survival is 76%, 49% and 25% for stages B2, C and D1 respectively. These results seem better than those reported with radical surgery alone and encourage the adoption of adjuvant chemotherapy to improve survival in patients with infiltrating bladder cancer.
Azab
M
M
Département de Médecine, Institut Gustave-Roussy, Villejuif.
Theodore
C
C
Cukier
J
J
Beurton
D
D
Gilles
E
E
Droz
J P
JP
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D011446:Prospective Studies; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
D004317:Doxorubicin; D002945:Cisplatin
Chimiothérapie adjuvante par adriamycine et cisplatine dans les cancers infiltrants de la vessie. Etude prospective sur 49 cas.